Compositions and Methods for Treating Neurogenic Disorders of the Pelvic Floor

a neurogenic disorder and pelvic floor technology, applied in the field of pelvic floor neurogenic disorders, can solve the problems of non-selective electrodes, incomplete bladder emptying, and “reflux” of urine into the kidneys, and achieve the effect of depolarization

Inactive Publication Date: 2014-01-23
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
View PDF8 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0024]In other aspects, provided herein is a method for treating sexual dysfunction in an individual in need thereof, the method comprising: administering an effective amount of a polynucleotide comprising a nucleotide sequence encoding a light-responsive opsin protein to the individual, wherein the opsin protein is expressed on the plasma membrane of a population of neurons responsible for the innervation of the genitalia of the individual, wherein the opsin protein induces depolarization of the neurons expressing the opsin protein in response to light, whereby the depolarization of the neurons responsible for the innervation of the genitalia restores sexual function.

Problems solved by technology

The muscles of the external urinary sphincter may also be affected by spinal cord injuries, resulting in a condition known as “dyssynergia.” Dyssynergia involves an inability of urinary sphincter muscles to relax when the bladder contracts, including active contraction in response to bladder voiding, preventing urine from flowing through the urethra and resulting in the incomplete emptying of the bladder and “reflux” of urine into the kidneys.
However, the electrode is non-selective and will stimulate every tissue and cell type that falls within its electrical field.
Thus, current neurostimulatory methods and devices cannot act locally with cell-type specificity to regulate the muscles and the nerves responsible for symptoms associated with detrusor hyperreflexia and external urinary sphincter dyssynergia.
SARS requires a sacral root rhizotomy to prevent DH / DSD, resulting in loss of sexual function.
Additionally, sacral root rhizotomy further damages the afferent pathways of the lower urinary tract, leading to bladder areflexia or the loss of bladder contraction.
However, in addition to the aforementioned loss of sexual function, SARS often results in very high bladder pressure that can cause near-term vesicoureteral reflux and has been associated, long-term, with renal failure.
However, all of these treatments suffer from considerable drawbacks, including the need for frequent repeat treatments (in the case of intermittent catherization and Botulinum Toxin administration), increased urinary tract infections (catheterization, stents, balloon dilation), increased incidence of septicemia (balloon dilation), and increased susceptibility to squamous-cell carcinoma (catheterization).
However, all of these methods suffer from considerable practical drawbacks and complications.
For example, damage to the pathways used by the autonomic nervous system to innervate the penis and clitoris may interrupt sexual arousal initiated by the central nervous system.
Lesions (e.g., injury, infection, or disease) of the somatic nervous pathways (i.e., any of the nerves associated with sensation or motion) may impair reflexogenic sexual function (i.e., involuntary, instinctive physiological response to a stimulus) and may interrupt tactile sensation needed to maintain sexual arousal.
Currently, there is no good long acting, cost effective, or clinically meaningful therapy that precisely targets the neural cells and associated muscles / organs responsible for these defects with the potential to bring about more physiologically normal micturition, bowel control, and sexual function in individuals with symptoms associated with neurogenic disorders of the pelvic floor.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and Methods for Treating Neurogenic Disorders of the Pelvic Floor
  • Compositions and Methods for Treating Neurogenic Disorders of the Pelvic Floor
  • Compositions and Methods for Treating Neurogenic Disorders of the Pelvic Floor

Examples

Experimental program
Comparison scheme
Effect test

example 1

Use of Optogenetic-Based Nerve Stimulation in an Animal Model of Detrusor External Sphincter Dysnergia (DSD) and Detrusor Hyperreflexia (DH)

[0187]This Example validates an animal model of DSD and DH for treatment with the optogenetic methods described herein. Cat models with spinal cord injuries have been used to recreate the human conditions of DSD and DH, having been validated using PET (Tai et al., 2004, Experimental Neurol., 190:171). There are also animal models of hyperreflexia in spinal cord injured (SCI) rats (Shaker et al., 2003, Neurourol Urodyn., 22(7):693-8) as well as in the EAE mouse, which is also a model for multiple sclerosis (Vignes et al., 2007, J. Physio. 578(Pt 2):439-50). In this Example, the membrane-targeted photoactivateable anion pump halorhodopsin from Natronomonas pharaonis (NpHR) is used to hyperpolarize the nerves responsible for the innervation of the detrusor muscle of the bladder and the external urinary sphincter.

Materials and Methods

[0188]Cats with...

example 2

Use of Light-Responsive Cation Channels to Provoke Depolarization-Induced Synaptic Depletion in An Animal Model of Detrusor External Sphincter Dysnergia (DSD) and Detrusor Hyperreflexia (DH)

[0203]This Example validates an animal model of DSD and DH for treatment with the optogenetic methods described above whereby urinary function is restored via selective depolarization-induced synaptic depletion of the detrusor innervations arising from the sacral spinal nerves and the external urinary sphincter innervations of the pudendal nerve. The feline or rodent animal models are identical to those used in Example 1.

[0204]Yellow fluorescent protein (YFP)-labeled SSFO (pAAV-Thy1-hChR2 (E123T / T159C)-EYFP; see www(dot)optogenetics(dot)org) in an AAV1 viral vector and under control of the feline Thy1 promoter is injected directly into the somatic motor neuron cell body of the sacral spinal nerves (responsible for detrusor innervations) and into Onuf's nucleus (responsible for external urinary sp...

example 3

AAV Vector Constructs

[0207]The following Adenoassociated virus (AAV) constructs were generated: 1) AAV1:hsyn-ChR2-EYFP (AAV1 comprising a nucleotide sequence encoding a ChR2-eYFP fusion protein operably linked to a human synapsin 1 promoter); 2) AAV6-hsyn-ChR2-EYFP (AAV6 comprising a nucleotide sequence encoding a ChR2-eYFP fusion protein operably linked to a human synapsin 1 promoter); 3) AAV1-hsyn-NpHR-EYFP (AAV 1 comprising a nucleotide sequence encoding an NpHR 3.0-EYFP fusion protein, operably linked to a human synapsin 1 promoter); 4) AAV6-hsyn-NpHR-EYFP (AAV6 comprising a nucleotide sequence encoding an NpHR 3.0-EYFP fusion protein, operably linked to a human synapsin 1 promoter); 5) AAV1-hsyn-eARCH-EYFP (AAV1 comprising a nucleotide sequence encoding an eARCH 3.0-EYFP fusion protein, operably linked to a human synapsin 1 promoter).

[0208]Single-stranded DNA AAV viruses were produced in a baculovirus system (Virovek, Hayward, Calif.; as described in WO 2008 / 024998

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
wavelengthaaaaaaaaaa
wavelengthaaaaaaaaaa
Login to view more

Abstract

Provided herein are methods for the treatment of bladder dysfunction, including detrusor hyperreflexia and detrusor external sphincter dyssynergia, fecal incontinence, and / or sexual dysfunction in an individual via the use of stably expressed light-responsive opsin proteins capable of selective hyperpolarization or depolarization of the neural cells that innervate the muscles responsible for physiologic functioning of urinary bladder, external urinary sphincter, external anal sphincter, and the male and female genitalia.

Description

CROSS-REFERENCE[0001]This application claims the benefit of U.S. Provisional Patent Application No. 61 / 601,298, filed Feb. 21, 2012, which application is incorporated herein by reference in its entirety.TECHNICAL FIELD[0002]This application pertains to methods for treating neurogenic disorders of the pelvic floor including bladder dysfunction, fecal incontinence, and sexual dysfunction in an individual, via the use of stably expressed light-responsive opsin proteins capable of selectively altering the membrane potential of the neural cells that innervate the muscles and organs responsible for urinary, rectal, and sexual function.INTRODUCTION[0003]“Optogenetics” refers to the combination of genetic and optical methods used to control specific events in targeted cells of living tissue, even within freely moving mammals and other animals, with the temporal precision (millisecond-timescale) needed to keep pace with functioning intact biological systems. The hallmark of optogenetics is t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/17
CPCA61K38/177A61K48/005A61K49/0008C12N2750/14141A61P1/00A61P1/10A61P1/12A61P13/02A61P13/10A61P15/00A61P15/08A61P15/10A61P21/00A61P25/00A61P25/02A61P31/00A61P35/00A61P43/00A61P5/00A61P9/00A61P3/10A61N5/062A61N2005/0663
Inventor DEISSEROTH, KARL A.ADEN, ELIZABETH R.GRADINARU, VIVIANADELP, SCOTT L.
Owner THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products